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HyperthermiaHyperthermia, i.e. heating the tumor to a temperature of 40–43 °C is considered bymany a valuable treatment to
sensitize tumor cells to radiotherapy and chemotherapy. In recent randomized trials the great potential of adding
hyperthermia to chemotherapy was demonstrated for treatment of high risk soft tissue sarcoma: +11.4% 5 yrs.
overall survival (OS) and for ovarian cancer with peritoneal involvement nearly +12months OS gain. As a result
interest in combining chemotherapy with hyperthermia, i.e. thermochemotherapy, is growing. Extensive biolog-
ical research has revealed that hyperthermia causes multiple effects, from direct cell kill to improved oxygena-
tion, whereby each effect has a specific temperature range. Thermal sensitization of the tumor cell for
chemotherapy occurs for many drugs at temperatures ranging from 40 to 42 °C with little additional increase
of sensitization at higher temperatures. Increasing perfusion/oxygenation and increased extravasation are two
other important hyperthermia induced mechanisms. The combination of free drug and hyperthermia has not
been found to increase tumor drug concentration. Hence, enhanced effectiveness of free drug will depend on
the thermal sensitization of the tumor cells for the applied drug. In contrast to free drugs, experimental animal
studies combining hyperthermia and thermo-sensitive liposomal (TSL) drugs delivery have demonstrated to re-
sult in a substantial increase of the drug concentration in the tumor. For TSL based chemotherapy, hyperthermia
is critical to both increase perfusion and extravasation aswell as to trigger TSL drug release,whereby the temper-
ature controlled induction of a local high drug concentration in a highly permeable vessel is driving the enhanced
druguptake in the tumor. Increaseddrug concentrations up to 26 times have been reported in rodents. Good con-
trol of the tissue temperature is required to keep temperatures below 43 °C to prevent vascular stasis. Further,
careful timing of the drug application relative to the start of heating is required to benefit optimal from the com-
bined treatment. From the available experimental data it follows that irrespective whether chemotherapy is ap-
plied as free drug or using a thermal sensitive liposomal carrier, the optimal thermal dose for
thermochemotherapy should be 40–42 °C for 30–60 min, i.e. equivalent to a CEM43 of 1–15 min. Timing is crit-
ical: most free drug should be applied simultaneous with heating, whereas TSL drugs should be applied
20–30 min after the start of hyperthermia.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The publication of Cavaliere et al. [1] in 1967 was the first clinical
study to demonstrate the clinical potential of hyperthermia to boost
the effectiveness of chemotherapy. In their study Cavaliere et al. showed
that hyperthermic (41.5–43.5 °C) regional perfusion of isolated limbs
resulted in complete disappearance of the tumor in 10 of 22 patients.
The subsequently general interest raised in the combined application
of heat and drugs is believed to be the fundament of today's interest
in the application of hyperthermia as sensitizing agent specific for che-
motherapy but also for its combination with radiotherapy.Rhoon).
.V. This is an open access article und
ranckena and T.L.M. tenHage
, https://doi.org/10.1016/j.addDuring the last decades extensive biological research has been per-
formed to identify the biological mechanisms induced by hyperthermia
alone as well as in combination with radiotherapy or chemotherapy. As
a result of this research hyperthermia is considered by many a strong if
not the strongest biological sensitizer for radiotherapy and chemother-
apy [2–5]. In early years the general strategy was that independent
whether hyperthermiawas combinedwith radiotherapy or chemother-
apy the aim should be to apply hyperthermia with the minimum tem-
perature in the tumor exceeding 42 °C to maximize the effect of
induced direct cell kill and direct sensitization of radiotherapy or che-
motherapy. However, the experience obtained from early clinical stud-
ies showed that with the hyperthermia equipment available in the late
1980's applying hyperthermia at a minimum tumor temperature of
42 °C was not realistic [6–8]. In contrast, the numerous positiveer the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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lished in the 1990's and early 2000's reported that the impressive and
statistically significant improved treatment outcome (local-control
and survival) were obtained with average target temperatures in the
range of 40–42 °C [9–18]. Hence, indicating that the ability of hyperther-
mia to improve tumor oxygenation and reduce repair of DNA damage
are dominating factors explaining the heat induced enhancement of ra-
diotherapy or chemotherapy effectiveness.1.1. Phase III trials for chemotherapy plus hyperthermia
The current revival of clinical interest in combining chemotherapy
plus hyperthermia follows publication of several phase III trials
[19–37] in the last two decades with encouraging results for different
tumor entities. Table 1 provides a list of phase III studies comparing che-
motherapy vs chemotherapy plus hyperthermia for which a full paper
has been published in a peer reviewed journal. The 2003 publication
of the results of the phase III study of Hyperthermic Intravesical Chemo-
therapy (HIVEC) in high-risk non-muscle invasive bladder cancer by
Colombo et al. reporting an increase of 17 to 57% in the 2-yrs recurrence
free survival marks a growing interest in HIVEC. Long term results were
published in 2011 showing a three-fold increase in the 10 yrs. DFS for
the HIVEC group (53% MMC + hyperthermia vs 17% MMC-alone) and
confirmed the encouraging early results [19,20]. Other randomized con-
trolled trials (RCTs) showed the impact of doubling the MMC dose on
treatment outcome [25,26]. Arends et al. [27] compared for the same
patient group the efficiency of standard therapy with BCG with
MMC + hyperthermia and found in the group of patient analyzed ac-
cording to the treatment delivered per protocol (pp) a statistical signif-
icant improved recurrence free survival at 2 yr, increase from 65% for
BCG to 82% for MMC + hyperthermia. Lammers et al. [38] conclude in
their systemic review that MMC based thermochemotherapy reduces
the risk of NMIBC recurrence by 59% when compared with MMC
alone. Overall bladder preservation after thermochemotherapy is
87.6%. However, due to the limited number of randomized trials and dif-
ferent study designs, definitive conclusions cannot be drawn with re-
spect to time to recurrence and time to progression [38].
The application of hyperthermic intraperitoneal chemotherapy
(HIPEC) has been investigated as 1) an adjuvant treatment in close con-
nection to primary surgery of patients with gastric cancer and colon
cancer to reduce the risk for a peritoneal recurrence/metastases or
2) as a follow-up treatment for patients that already present with intra-
peritoneal tumor growth after earlier treatment. Five RCTs addressed
the potential of HIPEC to prevent peritoneal carcinomatosis [28–32].
Three of the five studies report a benefit on treatment outcome for the
treatment including HIPEC [29–31]. However, themost recent and larg-
est RCT by Klaver et al. [32] finds that adding HIPEC to standard treat-
ment (surgery plus adjuvant systemic chemotherapy) does not
translate in a higher probability of patients with peritoneal free survival
at 18months after treatment. The use of HIPEC as treatment for patients
already presenting with peritoneal carcinomatosis of colorectal, gastric
and ovarium cancer has been published in four RCTs [22,33–36]. All
four RCTs show that adding HIPEC to cytoreductive surgery (CRS) re-
sults in an improved overall survival. The study by Van Driel et al. [22]
on the use of HIPEC in ovarian cancer reports longermedian overall sur-
vival for the surgery plus HIPEC arm by nearly 12months. However, fol-
lowing the results of the PRODIGE 7 trial [39]1 investigating HIPEC with
oxaliplatin for 30 min in a well-defined cohort of patients who are
meeting precise inclusion and exclusion criteria, there is ongoing dis-
cussion whether HIPEC should remain first line treatment for patients
with peritoneal carcinomatosis of colorectal origin [40,41]. The use of
chemotherapy plus hyperthermia for the treatment of solid tumors
has been reported in two RCTs [23,24,37] with the most recent study1 data only available as abstract
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thermochemotherapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addby Issels et al. [23,24] showing an impressive increase in median overall
survival from 6.2 yrs. for neoadjuvant chemotherapy (EIA) alone to
15.4 yrs. when hyperthermia is added. Within Germany the positive
outcome of this phase III study translated in the requirement that any
Soft Tissue Sarcoma center must provide hyperthermia.
Notably, in all these level I evidence thermochemotherapy studies
the average temperatures applied ranged from 40 to 42 °C, i.e. temper-
atures that can be achieved realistically in clinical practice with current
hyperthermia technology. The promising clinical results, together with
highly innovative approaches for advanced drug delivery using smart
temperature triggered drug carriers [42,43] has invoked a new interest
from the medical oncology community in hyperthermia. To address the
question on what thermal dose should be best applied in the combined
treatment of chemotherapy plus hyperthermia this review identifies
three strategies of interaction alongwhich hyperthermiamay act to en-
hance the effectiveness of chemotherapy: thermal sensitization, ther-
mal enhanced perfusion and thermal enhanced extravasation. An
additional consideration for the applied thermal dose follows from the
temperature required to trigger thermal drug release using smart drug
delivery carriers. For each strategy a potential relation with thermal
dose is discussed. A brief discussion is included on thermal dose effect
relationship in their clinical data. The review ends with summarizing
the required thermal dose for thermochemotherapy andhow this trans-
late in demands for current and future hyperthermia technology.
2. Chemotherapy and tumor microenvironment
Characteristic for solid tumors is their chaotic vasculature. As a result
tumor growth is highly controlled by thepoormicroenvironmental con-
ditions. At the same time themicroenvironment is highly determinative
for the efficacy of the chemotherapy. In general the vasculature network
of the tumor is primitive and chaotically developed resulting in inade-
quate supply of oxygen and nutrients as well as inadequate removal of
waste products. As a consequence, tumors generally contain regions of
low oxygenation (hypoxia) that are associated with elevated interstitial
fluid pressure, glycolysis, low pH and reduced bioenergetic status.
Tumor cells under these conditions are still viable but demonstrate sub-
stantial resistance to conventional radiotherapy and chemotherapy
[44–49]. Although, there is growing understanding that poor microen-
vironmental conditions also influences the tumors aggressiveness and
metastatic spread by modifying intracellular pathways [48], hypoxia is
still considered a major critical factor for treatment resistance [45,50].
A secondary effect of the poor vascular network of tumor is that vascular
based drug delivery is restricted with the lowest drug concentration at
the hypoxic regions. In addition with enlarged distances between
tumor vessels, drugs have to diffuse over larger distances, further
compromising drug concentration at tumors cells located away of func-
tional vessels.
Conventional chemotherapy is mostly effective against rapidly di-
viding cells, whereby the agents are non-selective. Although, aimed to
kill preferentially tumor cells the chemotherapy will also damage the
rapidly dividing normal healthy tissue cells, causing severe and unin-
tended and undesirable side effects. The above explained tumor charac-
teristics causes the bio-accessibility of the drug to the tumors cells to be
poor, forwhich higher systemic drug doses are required to improve out-
come. However, higher doses also lead to increased toxicity and inci-
dence of multi-drug resistance [51,52]. Therefore it is desirable to
combine chemotherapy with other therapies to enhance drug delivery
at the site of the tumor, targeting to enhance drug selectivity and in-
crease sensitivity, i.e. sensitization, of the tumor cells for the drug
applied.
3. Hyperthermia: biological effects
Research on the biological effects of hyperthermia during the last de-
cades focused on the so-called mild hyperthermia, i.e. temperaturen, Amoderate thermal dose is sufficient for effective free and TSL based
r.2020.03.006
Table 1
Randomized Trials of chemotherapy and hyperthermia.
Authors Tumor N Control arm Study arm Temperature
[°C] and
duration
[min]
Outcome Control
arm
Study
arm
HIVEC
Colombo et al.
2003, 2011.
[19,20]
NMIBC: Intermediate or high
risk
83 MMC-alone:
20 mg/50 ml
MMC + HT 40–44 °C;
40–60 min.
Recurrence
10 yrs. DFS
(91ma)
80%
15%
40%b
53%
Gofrit et al.
2004. [25]
NMIBC: Ta/1 G2–3
high-risk
52 MMC + HT
20 mg/50 ml
MMC + HT 40 mg/50 ml 40–44 °C;
40 min.
Recurrence
(15.2ma)
37.5%
mean
10 m.
19%
after
13.7 m.
Moskovitz
et al. 2005.
[26]
NIMBC: Intermediate and
high-risk
47 MMC + HT
20 mg/50 ml
MMC + HT 40 mg/50 ml 40–44 °C;
60 min.
Recurrence
FU N 10 m
9%
after
10 m.
20%
after 9 m.
Arends et al.
2016. [27]
NIMBC: Intermediate and
high-risk
190 BCG (full dose) MMC + HT
20 mg/50 ml MMC
42 ± 2 °C;
60 min.
RFS at 24 m
ITT analysis
PP analysis
65%
65%
78%
82%
HIPEC in adjuvant setting to prevent peritoneal recurrence
Hamazoe et al.
1994. [28]
gastric cancer 82 surgery alone Surgery+HIPEC MMC (10 mg/l) ~43 °C;
50–60 min.
5 yrs. OS 52.5% 64.3%
Fujimoto et al.
1999. [29]
Advanced gastric cancer 141 surgery alone Surgery+ HIPEC
MMC 10 mg/l
~43 °C;
120 min.
OS 2 yrs
OS 4 yrs
OS 8 yrs
77%
58%
49%
88%
76%
62%
Yonemura
et al. 2001.
[30]
T2–4 gastric cancer 139 #1 - CRS #2 -CRS + HIPEC 30 mg MMC+
300 mg cisp/6-8lt
#3 -CRS + normotherm HIPEC 30 mg
MMC+ 300 mg cisp/6-8lt
#2: 42–43 °C
#3: 37 °C
5 yr OS #1–42% #2–61%
(#1 vs
#2)
#3–43%
(#2 vs
#3)
Cui et al. 2014.
[31]
Advanced gastric cancer 192 #1 Control: surgery
alone
#2 -Preop chemo-Surgery
#3 -Surgery+HIPEC
#4 -Preop. Chemo-Surgery-HIPEC
41–43 °C;
90 min.
3 yrs. OS 35.4% #2–62.5%
#3–58.3%
#4–75.0%
Klaver et al.
2019. [32]
Colon Cancer 204 Resection primary
tumor adjuvant syst.
Chemotherapy
Standard plus HIPEC iv 5FU
(400 mg/m2) + leucovorin
(20 mg/m2) plus peritoneal
oxaliplatin (460 mg/m2)
42–43 °C;
30 min.
Peritoneal
free survival
at 18 m.
76.2% 80.9%
HIPEC for treatment of peritoneal metastasis
Verwaal et al.
2003, 2008.
[33,34]
peritoneal
carcinomatosis of colorectal
cancer
105 Systemic chemotherapy
(5FU leucovorin)
CRS + HIPEC (MMC 70 mg max)
+ syst. Chemotherapy
40–42 °C;
90 min.
median PFS
median DSS
(94ma)
7.7 m.
12.6 m.
12.6 m.
22.2 m.
Yang et al.
2011. [35]
Gastric cancer 68 CRS-alone CRS + HIPEC (Cisp. 120 mg + MMC
30 mg in 6lt)
43 ± 0.5 °C;
60–90 min.
Median OS 6.5 m. 11.0 m.
Spillotis et al.
2015. [36]
Recurrent Ovarian cancer
after initial surgery and
systemic chemo
120 CRS followed by
systemic chemo
CRS + HIPEC (Cisp+Paclitaxel or
doxorubicin+paclitaxel/MMC)
+ systemic chemo
42.5 °C;
60 min.
Mean OS
OS at 3 yrs
13.4 m.
18%
26.7 m.
75%
Van Driel et al.
2018. [22]
Ovarian Cancer 245 CRS CRS + HIPEC (100 mg/m2 Cispl) 40 °C;
90 min.
median OS 33.9 m. 45.7 m.
Conventional chemo plus hyperthermia
Sugimachi
et al. 1994.
[37]
Oesophageal Ca 40 Chemotherapy (30 mg
Bleo +50 mg Cisp)
+ surgery
Chemotherapy +HT (intraluminal) 42–45 °C;
30 min.
Pathological
effectiveness
14% 58%
Issels et al.
2010, 2018.
[23,24]
High risk soft tissue
sarcoma
341 neo-adjuvant
chemotherapy (EIA)
EIA plus
regional hyperthermia
40–42 °C;
60 min.;
7–8 heat
fractions
median OS
OS at 10 yrs.
(135ma)
6.2 yrs
42.7%
15.4 yrs
51.3%
HIVEC: Hyperthermie intravesical chemotherapy; HIPEC: Hyperthermic Intraperitoneal Chemotherapy.
BCG: bacillus Calmette-Guérin therapy; MMC: mitomycin C; HT: hyperthermia.
RFS: recurrence free survival; PFS: progression free survival; DSS: disease specific survival.
EIA: etoposide, ifosfamide, and Adriamacin.
CRS: cytoreductive surgery.
a Median follow-up.
b Bold is statistical significant.
3G.C. van Rhoon et al. / Advanced Drug Delivery Reviews xxx (2020) xxxranging of 39–42 °C, and revealed that the biological and physiological
effects induced by mild hyperthermia are capable of boosting the effec-
tiveness of chemotherapy and radiotherapy to kill tumor cells
[2–5,47,53–56]. Excellent reviews by Issels [56], van den Tempel et al.
[55], Oei et al. [5,57], Dewhirst et al. [2] provide clear and detailed over-
views of the variousmacroscopic (perfusion, tumormicroenvironment)
and microscopic (evading DNA repair, blocking cell survival, mechanis-
tic sensitization, cellular thermal stress response) biological effects in-
duced by mild hyperthermia.Please cite this article as: G.C. vanRhoon,M. Franckena and T.L.M. tenHage
thermochemotherapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addIndependent of any synergistic action between chemotherapy and
hyperthermia is the ability of hyperthermia to selectively kill tumor
cells under hypoxic and acidic conditions at temperatures of 42 °C and
up. A direct consequence of the poor blood flow in the hypoxic regions
is that the limited heat dissipation by perfusion makes them easy to
heat, i.e. higher temperatures are more easily achieved. It is widely ac-
cepted that tumor cells under hypoxic and acidic conditions are selec-
tively killed by hyperthermia as they are much more sensitive to heat
than cells in a well‑oxygenated environment [58,59]. In addition, atn, Amoderate thermal dose is sufficient for effective free and TSL based
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4 G.C. van Rhoon et al. / Advanced Drug Delivery Reviews xxx (2020) xxxtemperatures between 41 and 43 °C hyperthermia increasesmembrane
permeability (thermal sensitization) and reduces repair of DNA dam-
age, both increasing the effectiveness of drugs to kill tumor cells
[4,55]. Finally, already at relative low temperatures perfusion and
extravagation is enhanced resulting in an increased drug delivery and
availability at the tumor [46,60–62]. The temperature ranges for the dif-
ferent effects are illustrated in Fig. 1.
Together the above illustrates that mild hyperthermia is an ideal
complementary treatment to combine with chemotherapy as it pro-
vides all the required benefits in a single treatment to enhance killing
of the hypoxic tumor cells, i.e. the cells relatively insensitive for chemo-
therapy and to boost drug effectiveness. The plethora of thermal effects
can beused to enhance the effectiveness of chemotherapy following dif-
ferent objectives (Fig. 2). The first and simplest one aims only at direct
thermal sensitization of the applied drug. The second objective aims
only at temperature modulated enhanced perfusion and extravasation
to increase tumor drug concentration, hyperthermia is given prior to
the administration of the chemotherapy. In the third objective the aim
is to combine the increase in perfusion and extravasation with a tem-
perature triggered drug release specific at the site of the target in
order to maximize drug concentration in the tumor. Often it will be dif-
ficult to apply the treatmentwith a clear separation between the effects
of objective one and two, with time interval between drug and hyper-
thermia administration, absolute temperature and duration of heating
as discriminating factors between both objectives. This third objective
is more exclusive as it requires the use of chemotherapy delivered by
thermal sensitive liposomes. This approach is currently bymany consid-
ered to be the most potent one to improve tumor specific drug
absorption.
4. Current use of thermal dose in thermochemotherapy
Essential for the development of optimal treatment strategies for
thermochemotherapy is that besides the dose prescription of the che-
motherapy, the quality of the applied hyperthermia treatment is quan-
tified using an appropriate thermal dose parameter. The answer towhat
is the appropriate thermal dose parameter is not easily given. The most
important feature of a thermal dose parameter is that it should be able
to reflect the dominant mechanisms of interaction between the drug
used and the level of heating achieved [63].
Studies investigating the thermal dose effect relationship in
thermochemotherapy are extremely rare [64–66]. In contrast, finding
a thermal dose effect relationship for the combined radiotherapy andFig. 1. The graph shows for the different biological mechanisms of hyperthermia the threshold
effect ceases or transfer in a next higher one. As example perfusion start to increase from39 °C an
transfer in direct cell death at 44 °C or higher [75].
Please cite this article as: G.C. van Rhoon,M. Franckena and T.L.M. tenHage
thermochemotherapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addhyperthermia treatment has received interest from early clinical appli-
cation. Over the past decadesmany clinical studies have been published
demonstrating thermal dose effect relations using various expression of
temperature alone (average-, minimum temperature) or as parameter
integrating the combined effect of time and temperature [67–73]. In
current daily practice, the cumulative equivalent minutes at 43 °C
(CEM43) model is the most common used model to report the quality
or thermal dose of the hyperthermia treatment applied [2,74,75]. The
CEM43 model provides a normalizing tool to convert various time-
temperature exposures to an equivalent exposure time in minutes at a
reference temperature, commonly 43 °C, using the formula:
CEM43 ¼
Zt
0
R 43−Tð Þdt min½ 
In this formula T represents the actual applied temperature of the
target tissue and R the factor to compensate for a 1 °C temperature
change. R is experimental determined and has been set at a value of
0.5 for T N 43 °C, i.e. the equivalent time doubles per degree temperature
increase, and 0.25 for T ≤ 43 °C, i.e. the equivalent timedecrease by a fac-
tor of four per degree temperature decrease.
Although the model is widely used in studies searching for thermal
dose effect relationships, the ability of the CEM43 concept to predict
thermal initiated cell kill has a serious number of limitations as ex-
plained in detail elsewhere [75]. For patients with locally advanced cer-
vical cancer (LACC) that were treated by thermoradiotherapy, with
hyperthermia applied using a fixed exposure time and number of treat-
ments, CEM43 and Trise has been shown to correlate with treatment
outcome in a large study (n= 420), independently of the radiotherapy
dose parameters [68]. TRISE is a thermal dose parameter based on the
temperature exceeded by 50% of measurement sites and duration of
heating [68]. Most recent, the predictive value of Trise has been repli-
cated in an independent study involving 227 patients diagnosed with
LACC [76]. Besides these clinical studies, there is still ongoing research
in developing multiparameter mathematical models to capture the
complex interaction of hyperthermia with tumor and normal tissue
cells in a single formula [77–80].
In their excellent review Issels et al. [81] identify six hallmarks of hy-
perthermia as targeted therapy that should be consideredwhen design-
ing a clinical trial combining chemotherapy and hyperthermia. For four
of the six hallmarks (blocking cell survival, inducing cellular stress re-
sponse, evading DNA repair, sensitization to radiotherapy andtemperature to initiate the effect and if applicable a maximum temperature at which the
d around42 °C vascular stasiswill develop;DNA repair inhibition starts around41.5 °C and
n, Amoderate thermal dose is sufficient for effective free and TSL based
r.2020.03.006
Fig. 2. Schematic representation of the different synergistic combinations of chemotherapy and hyperthermia, with as challenges to increase drug concentration and focus heating to the
tumor. Enhanced treatment outcomemight follow by heat: enhancing the effectiveness of the chemotherapy, improved drug delivery by perfusion and extravasation, boosting local drug
release at the tumor by using thermo-sensitive liposome drug carriers.
Table 2
Thermal enhancement ratio for various chemotherapeutics and as function of tempera-
ture for a FSa-II and mammary tumor.
Thermal enhancement ratio (TER)
Temperature [°C] 40–42 42.5–44 40–42 42.5–44
Tumortype FSa-II Mammary Ca
Drug
Cisplatin 1.5 ± 0.2 1.6 ± 0.2 2.9 3.6
Cyclophosphamide 2.3 ± 0.3 2.7 ± 0.4 1.6 ± 0.1
Ifosfamide (30 min) 1.5 ± 0.3
Ifosfamide (90 min) 3.6 ± 0.5
Melphalan 3.6 ± 0.5
BCNU 2.3 ± 0.2 2.7 ± 0.2
Bleomycin 1.2 ± 0.4 1.7 ± 0.3
Mytomycin C 1.0 2.8 ± 0.5
5-Fluorouracil 1.0 1.0
Doxorubicin 1.0 1.0 1.0 1.0
Data taken from Urano et al. [90].
5G.C. van Rhoon et al. / Advanced Drug Delivery Reviews xxx (2020) xxxchemotherapy) the relation of the magnitude of the biological effect of
the hallmark with thermal dose, i.e. temperature and duration of expo-
sure, is exponential and in general following the CEM43 model
[4,5,53,58,82,83]. The thermal dose effect relationship for the hallmark
‘modulating immune response’ is less clear, still being subject of re-
search [17]. For the last hallmark ‘changing tumor environment’ the
dominant biologicalmechanism is the ability of hyperthermia to change
the tumor blood perfusion and vascular permeability [84,85],with asso-
ciated physiological improvements. The relation of thermal dose with
increased perfusion is complex but can also be covered with the
CEM43 model. In summary, application of the CEM43 model to inte-
grate the history of the applied temperature time profile has a rational
from the biological and physiological effects and is to be considered as
a practical solution even though it is based on direct cell kill. For a
more extensive discussion see recent reviews on thermal dose parame-
ters [2,53,75,86].
4.1. Direct sensitization of chemotherapy by hyperthermia
Although in general the combined treatment of chemotherapy with
hyperthermia will increase treatment effectiveness the underlying
mechanism for the thermal enhancement is complex and varies with
the type of drug. Earlier Issels has classified the interaction of heat and
chemotherapy in three categories [56,87]:
1. Independent, hyperthermia and the drug appear to act by inde-
pendent mechanisms.
2. Additive, hyperthermia results in additional damage: with in-
creasing temperature the effectiveness of the cytotoxic mechanism is
enhanced.
3. Synergistic, little or no thermal sensitization occurs at low temper-
atures, but marked sensitization occurs at temperatures above 42 °C.
According to Issels [56,88] antimetabolites (e. g. 5-fluorouracil,
methotrexate) and vinca-alkaloids or taxanes (paclitaxel and doce-
taxel) do not show any significant thermal enhancement of cytotoxicity,
i.e. the combined effect of heat and drug exposure upon cell survival is
equalwith the effect of each individual treatment alone (=independent
action). The efficacy of alkylating agents (e.g. cyclophosphamide,
ifosfamide and melphalan) and nitrosoureas (e.g. BCNU)was enhanced
by hyperthermia, both in vitro and in vivo (additive). For these agents
timing of drug and heat delivery was shown to be important with, inPlease cite this article as: G.C. vanRhoon,M. Franckena and T.L.M. tenHage
thermochemotherapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addgeneral,maximumeffect in vivowhen the agentswere applied immedi-
ately before hyperthermia. Gemcitabine (2′,2′-difluorodesocycytidine)
is an exception: simultaneous application led to decreased cytotoxicity,
while an interval of 24 h led to an enhanced cell killing [89]. Some drugs
are only enhanced, e.g. bleomycin, above a threshold temperature of
42.5 °C, while platinum drugs and alkylating agents show a gradual in-
crease of the effect with increasing temperatures. For cisplatin and ana-
logues (e.g. carboplatin) a potentiating effect of hyperthermia on
cytotoxicity has been demonstrated already at relatively low tempera-
tures of 40.5 °C. Table 2 shows in vivo TER-values as reported by
Urano et al. for common drugs and various tumor types as measured
in animal experiments. In general, in vivo TER varies between drugs
and tumors, but if a TER exists a common value is between 1.5 and 2.5
in the temperature range of 40–42.5 °C with only a relative small in-
crease at higher temperatures. However, for some specific combinations
of drugs and tumor types the TERmay reach higher values,whereby one
should note that for temperatures above 43 °C a part of the increase in
the TER was reported to be a contribution of direct thermal cell kill. In-
teresting for Ifosfamide is that increasing the treatment time from 30 to
90 min at 41.5 °C increased the TER from 1.52 to 3.60 [90].n, Amoderate thermal dose is sufficient for effective free and TSL based
r.2020.03.006
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ment approach, experimental researchhas shown that chemoresistance
could be reversed, at least partially, by the addition of heat for several
anticancer drugs (e.g. CDDP, mitomycin C, anthracyclines, BCNU,
melphalan) including CDDP especially for CDDP-resistant cells
[91,92]. The experimental results are recently supported by
Wessalowski et al.. In a phase 2 study, involving 44 children and
adolescenst with refractory or recurrent malignant germ-cell tu-
mors, they report encouraging long term results for local tumor
control after retreating them using the same chemotherapy in com-
bination hyperthermia as a salvage protocol [156].
Clearly, for designing the strategy to combine chemotherapy and hy-
perthermia in primary or recurrent setting a good understanding of the
actionmechanismbetween the two agents is crucial to achievemaximal
clinical effect and to define realistic demands on sequence of and inter-
val time between each agent, overall treatment time as well as the re-
quired optimal tumor temperature range (40–44 °C).4.2. Hyperthermia and perfusion
The first physiological reaction of human tissue on an increase of tis-
sue temperature is an increase in blood perfusion. This physiological re-
sponse has however, a complex character and depending on the
exposure time and height of the temperature, opposite effects on
tumor perfusion [62,93–98].
Within the hyperthermia field consensus exist that the changes in
perfusion are paralleled by similar changes in tumor oxygenation.
Heat induced perfusion effects and presumably also the proportionality
between perfusion and oxygenation changes, varies between species,
tumor types, the applied thermal dose, the time of measurement (di-
rectly after heat or 24 h later), number of heat fractions and also the
rate of heating [60,93–96]. The relation between improved perfusion
and oxygenation is important as many anticancer drugs require molec-
ular oxygen to bemaximally cytotoxic (i.e. hypoxia can be a direct cause
of therapeutic resistance) and tumor cell resistance is caused byhypoxia
induced alterations in the cellular genome and proteome [48,99,100]. In
animal studies, improvement in tumor oxygenation has been shown to
increase tumor cell killing by cyclophosphamide, 1,3-bis(2-
chloroethyl)-1-nitrosourea, Doxorubicin, and Taxol [101–103]. As reox-
ygenation occurs at relatively low thermal doses this should reflect in
the thermal goals of hyperthermia [104].
Literature has shown that already a slight elevation of tissue temper-
ature to 39–40 °C results in an increase of tumor blood flow and im-
proved microcirculation [60,62,95,105]. When tumor temperature is
higher and the exposure time is longer, tumor perfusion will increase
further until a threshold thermal dose is reached from where tumor
blood flow will decrease. In general heating to temperatures between
40 and 42 °C for 30–60min are found to increase perfusion and oxygen-
ation, although this will vary between tumor types and species. For tu-
mors vascular stasis is expected to occur after heating for 60 to 120min
at temperatures around 43 °C, while for normal tissue this is reported to
occur after 60min heating at 45–47 °C [97,106].Whereas for tumors the
reported increase in perfusion is a factor two, the increase in perfusion
for normal tissues like muscle and skin can reach a factor 10. Further,
it has been shown that the resting perfusion levels and the ability to in-
crease perfusion changes when multiple hyperthermia treatments are
administered with 1–2 days interval, with the highest increase after
the first heat exposure and stabilizing values for subsequent exposures
[96]. Nearly all studies investigating the response of tumor and normal
tissue perfusion on the thermal dose of the heat exposure have been ob-
tained in rodents. Despite the general consensus that hyperthermia im-
proves blood perfusion, studies in humans to assess tumor perfusion
during or shortly after hyperthermia are still scarce and provide incon-
clusive data reporting increasing aswell as decreasing tumor blood flow
[107–113].Please cite this article as: G.C. van Rhoon,M. Franckena and T.L.M. tenHage
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delivery to a tumor with high interstitial fluid pressure (IFP) was re-
cently demonstrated by Stapleton et al. [49]. They applied hyperthermia
to a MDA-MB-231 human breast adenocarcinoma tumor modal located
in the lower abdominal mammary fat pad of female SCIDmice. Heating
the tumor for 20 min at 42 °C resulted in a rapid decrease of IFP to nor-
mal tissue levels, whereby the authors indicate that the initial bulk de-
crease in IFP following hyperthermia appeared to be driven by a
significant increase in perfusion and vascular volume during the heat
application. Applying a single dose of nanotherapeutics (Doxil) com-
bined with heat resulted in an up to 2.2 fold increase in the enhanced
volume fraction. Radial analysis also revealed greater concentration at
the center of the tumor for heated vs the non-heated control animals.
In a low IFP tumor type (4 T1) adding heat did not enhanced drug
delivery.
In summary, hyperthermia at 40–42 °C for 30–60 min results in an
increased perfusion of the tumor during and immediately after heating,
that ismirrored by an improved pO2 level. A temperature of 43 °C can be
used but provides an increased risk of vascular stasis to occur after
60 min of heating. There is still an ongoing discussion on the duration
of the increased perfusion and pO2 level. However, when carefully
selecting the temperature and duration of heating, it seems reasonable
to assume that the improved conditions are indeed present for the du-
ration of drug circulation in the body as was shown by the Stapleton
et al. study [49].
4.3. Hyperthermia and extravasation
In a recent review Dewhirst and Secomb [114] have extensively
discussed current understanding of the complex path of transporting
drugs from the intravenous injection to the tumor cells to be killed.
Once the drug has arrived at the microvascular structure of the tumor,
thedrugs have to cross the layer of endothelial cells,which is considered
the main transport barrier. The ability of drugs to cross this barrier is
high for small lipophilic solutes (e.g. O2). Larger and hydrophilic solutes
can only pass through gaps between the endothelial cells [114,115]. As
explained above characteristic for tumors is their chaotic vasculature.
The fast proliferation of the endothelial cells in the tumor vessel wall
causes less tight junctions between the cells. In animalmodels it is com-
monly found that tumor vasculature is leaky (10× more than normal
vessels [114]) and that the large pores allow under normal conditions
passage of macromolecules or nanoparticles up to a diameter around
100 nm. Whether the same effect occurs also in humans is still debated
[116–119].Whenmild hyperthermia is applied to the tumor the higher
temperature causes an increase of perfusion and a shrinkage of the en-
dothelial cells (disaggregation of the endothelial cell cytoskeleton). This
process translates in enhanced extravasation though the thermally in-
duced larger pores between the endothelial cells. The potential impact
of the thermally induced enhanced extravasation on drug concentration
in the tumor has been investigated in multiple studies and the level of
extravasation was found to vary between tumors and to depend on
the intrinsic permeability of the tumor vasculature [106,120–129].
In-vivo experimental studies using the dorsal skin flap window
chamber model have shown the existence of a temperature threshold
for enhancing extravasation. Kong et al. [106] reports a threshold of
39 °C for extravasation in human SKOV-3 ovarian carcinoma, while for
temperatures from 40 to 42 °C nanoparticle extravasation increases
with temperature. Maximum extravasation was noted at the end of
the 60 min heat exposure at 42 °C. In the SKOV-3 tumor model
hemorrhaging and collapsing of vessels occurs after several minutes of
exposure at 43 °C. After heating the enhanced extravasation returned
to normal at 6 h post heating. Interesting they report the existence of
vascular thermotolerance: reheating of the tumor at 42 °C for 1 h
following 8 h after the first heating does not result in any increase of
extravasation. Li et al. [85,130] also used the window chamber model
to investigate thermal dose dependence of extravasation in fourn, Amoderate thermal dose is sufficient for effective free and TSL based
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Carcinoma (LLC) and humanBLMmelanoma cells. They found thatmin-
imum exposure time at 41 °C to initiate liposome extravasation differed
between tumors: murine BFS-1 sarcoma and LLC carcinoma required
20 min exposure while murine B16 melanoma and human BLM mela-
noma required 30 min exposure. In all tumors longer exposure time re-
sulted in higher extravasation levels and also diffusion from the
perivascular regions to deeper extravascular extracellular space (up to
27.5 μm from the vessels). Like Kong et al., Li et al. [85,106] reports
that tumor vasculature permeability was preserved after heating. In
their study Li et al. [85] found that permeability was preserved up to
8 h post-hyperthermia, though at a lesser extent and was completely
lost at 24 h post-hyperthermia. They also observed that extravasation
was heterogeneous within the tumor and also between different
tumor models with extravasation in LLC carcinoma Nmurine B16mela-
nomaNmurineBFS-1 sarcomaandhumanBLMmelanoma. In all studies
hyperthermia at 42 °C did not enable extravasation in normal vascula-
ture. In Fig. 3 the findings of Kong et al. and Li et al. are presented graph-
ically to illustrate the variability in the time needed to reach maximum
extravasation and the duration of enhanced extravasation as reported
by these authors.4.4. Hyperthermia and tumor drug concentration
Several studies investigated whether hyperthermia may increase
the concentration of free, i.e. non-encapsulated or non-liposomal,
drugs in tumor tissue [84,119,128,130,131]. Kong et al., and Manzoor
et al. reported no effect of hyperthermia on the tumor Dox concentra-
tion, when free DOX (5 mg/kg) was applied during heating at normal
temperature (34 °C) or at 41–42 °C [84,130]. In contrast Ponce et al. re-
ported a 2-fold increase of tumor DOX concentration when rats were
given free DOX (5 mg/kg) during hyperthermia [128]. In this study in-
terstitial tumor heating was used with a temperature gradient of
45–46 °C at the center to 39.0 °C at the tumor border. For other free
drugs (CDDP) or combinations (DOX + Alvespyimycin) application
during hyperthermia was not found to affect tumor drug concentration
[119,131]. The common opinion is that hyperthermia has little influence
on the absorption of free drugs by the tumor. In general a small molec-
ular weight chemotherapeutic, like DOX, has a short plasma half-live in
systemic circulation. The rapidly declining vascular drug concentration
will diminish the potential increase in drug absorption facilitated by hy-
perthermia driven enhanced vascular permeability.
In contrast to free drug the experimental animal studies combining
hyperthermia and thermo-sensitive liposomal (TSL) drugs delivery as
discussed above have demonstrated that this results in a substantialFig. 3. Schematic representation of the induction of enhanced extravasation induced by 60 m
hyperthermia at 40–42 °C for 30–60 min enhances extravasation quickly (30–60 min to maxim
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thermochemotherapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addincrease of the drug concentration in the tumor. Hereby, hyperthermia
is the component that controls the initiation of enhanced drug extrava-
sation, via increased tumor perfusion and permeability of the tumor
vessels, as well as to trigger TSL drug release at the tumor location.
The dominant factor in the process that drives the enhanced drug up-
take in the tumor is the ability to nearly instantly create a very high
drug concentration in the ‘leaky’ tumor vasculature [131,132]. In a re-
cent overview Hijnen et al. [133] analyzed 13 studies investigating
thermosensitive liposomal drug delivery mediated by hyperthermia
using high intensity focused ultrasound (HIFU) with or without MR-
guidance for temperature control. The benefit of MR-guided HIFU
heating is the ability to deliver a precise controlled, spatial and tempo-
ral, temperature distribution of ±1 °C to tumors with a diameter up to
4 cm. In their analyses, Hijnen et al. [133], found the doxorubicin con-
centration to be up to 26 times higher in heated vs non heated tumors.
Thermal dose reported varied from 15 to 40 min and 40–43 °C.
In summary, hyperthermia at 40–42 °C for 30–60 min is effective to
realize sensitization of the tumor cells for the applied chemotherapy
(TER 1.5–2.5) and to enhance tumor perfusion as well as extravasation
that lasts for several hours. Hyperthermia also triggers the site specific
TSL drug release that is mandatory to realize a high drug concentration
in the permeable tumor vasculature, i.e. the driving force that ultimately
results in the enhanced drug concentration in the tumor. Administra-
tion of chemotherapy and hyperthermia is preferably at the same time
or as closely together as possible. If multiple administrations of
thermochemotherapy are planned then these should be separated by
approximately 72 h to avoid vascular thermotolerance for heat.5. Role of thermal dose in heat mediated clinical drug delivery
When defining the strategy for an optimal thermal dose to be ap-
plied in thermochemotherapy it is important to consider the thermal
dose constraints from:
•the drug perspective, i.e. thermal sensitization and improved drug
uptake
•the perspective of patient tolerance, i.e. what thermal dose is safe
and tolerated,
•the technology perspective, what thermal dose can be applied
under good quality control and the ability for tumor specific delivery
of the hyperthermia.
In the end the balance between these three perspectives will be
made by the field, i.e. clinicians, patients and physicists. From an eco-
nomical perspective also manufacturers will contribute by providing
adequate equipment to easily apply thermochemotherapy, which can
be seamless integrated in existing treatment protocols, like for instancein of heating at 40–42 °C following the data presented in [85,106]. The figure shows that
um) followed by a decay over time and can last up to 24 h.
n, Amoderate thermal dose is sufficient for effective free and TSL based
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this quest to the optimal thermal dose and ultimately for acceptance of
thermochemotherapy.
5.1. Control of thermal dose
Many systemsexists to apply hyperthermia. Each systemhas its own
benefits with regard to its ability to preferentially heat the target vol-
ume, temperature monitoring, ease of use and total costs.
The most user friendly devices are the systems to apply hyperther-
mia in combination with drug perfusion as in HIPEC or HIVEC. In these
systems the perfusion liquid is heated to 42 °C and circulated in theperi-
toneum or bladder. The homogeneity of heating is dictated by quality of
perfusing the chemotherapeutic fluid through the organ. Clearly this is
easier to control for the bladder than for the peritoneum [134–138].
For heating of tumors at all other places in the body a large variety of
devices using either non-ionizing electromagnetic fields (EMF) or ultra-
sound (US) are available, with historical EMF systems being used more
commonly. With EMF systems large tumor sizes can be heated at any
location, superficial or deep, in the body. However, due to the long
wavelength of the EMF - frequency range 10–915MHz - the spatial res-
olution to control the heating pattern is limited to several centimeters.
US systems use ultrasound energy to heat tissue operate in a frequency
range of 0.5–8 MHz. The benefit of US is the short wavelength in tissue
resulting in a tight heating focus of mm dimension and a much larger
penetration depth in muscle tissue compared to EMF. A disadvantage
of US is the high reflection at air to soft tissue transitions as well as
the high absorption of US energy by bone. The small heating focus of
US makes it ideal for small tumors but for heating large tumors ad-
vanced scanning technology is required. So far heating tumors to
4–5 cm diameter has been demonstrated in anesthetized animals.
EMF systems have demonstrated in many clinical trials the ability to
heat large volume tumors with sizes in any direction to above 10 cm.
The ability to preferentially heat the target volume depends besides
the heating characteristics of the hyperthermia device also on the defi-
nition of the target volume. In HIVEC the target volume is the non-
muscle invasive bladder cancer (NMIBC). NMIBC is typically limited to
the bladder wall in which small tumor nodules at multiple locations
need to be heated [136]. A similar target definition applies for HIPEC
tumor locations [137]. As for both indications tumor depth is limited
to a few mm, heating by thermal conduction from the circulating and
heated drug fluid is a simple, efficient and effective method to heat
the tumor to 40–42 °C. However, for the larger solid tumors that are
heated by EMF or US techniques it is advisable to define the volume to
be heated larger than the gross tumor volume. For solid tumors the
inflowing blood will be at 37 °C and need some distance in order to
reach a temperature of 40–42 °C.When considering only themicroenvi-
ronment the target volume to be heated should be extended by 2-3 cm,
this should be sufficient to reach temperature equilibrium between the
smaller vessels and tumor tissue [139–142].
5.2. Measuring thermal dose
In general every hyperthermia system is equipped with multi-
sensor temperature probes to monitor the tissue temperature increase
at either (minimal-) invasive or superficial location. Fiber-optic or Bow-
man (thermistor probe with high resistance carbon wires for read-out)
temperature probes are immune for EMF and hence provide reliable
temperaturemeasurement. Fiber-optics probes can hold up to 6 sensors
and hence can measure a temperature profile along the thermometry
catheter track. Bowman probes are single sensor devices and use me-
chanical thermal mapping to measure a temperature profile along the
thermometry catheter. Thermocouple probes consist of twometal (cop-
per, constantan)wires and are sensitive to pick-up the RF-signal, and af-
fect aswell the EMF energy distribution pattern. Special RF-filtering and
read-out procedures have been introduced to minimize these effectsPlease cite this article as: G.C. van Rhoon,M. Franckena and T.L.M. tenHage
thermochemotherapy, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.add[143,144]. An advantage of thermocouples is that they are available
with up to 14 sensors in a single probe [145,146]. Accurate temperature
measurement using any of the invasive probes described are known to
have high absorption of the acoustic signal by the plastic tubing
encasing the fibers, thermistors and thermocouples. Rivens et al. [147]
report that very fine-wire thermocouples are often the method of
choice, though even these devices need special attention to avoidmove-
ment of the probe by the US and correction for thermal conductivity er-
rors in the high temperature gradient fields. A major short coming of
invasive thermometry is that it provides only information of the tem-
perature at the location of the probe. As both the clinician and the pa-
tient are not enthusiastic to place invasive thermometry catheters
knowledge about the 3D temperature distribution is extremely limited.
So it is no surprise that in the hyperthermia community great interest
exists for non-invasive thermometry using magnetic resonance imag-
ing, i.e. MR-thermometry. In ultrasound based hyperthermia the intro-
duction of non-invasive MR thermometry has enabled the ability
ofreal-time feedback control to carefully adapt the spatial
ultrasound energy deposition pattern to obtain an optimal thermal
dose delivery [148]. Also hybrid hyperthermia devices have been devel-
oped integrating MR-compatible, high energy EMF applicator to realize
MR-thermometry guided hyperthermia [149–154].
5.3. Defining thermal dose
From the above it follows that adding hyperthermia to chemother-
apy may result in:
•Thermal sensitization of tumor cells for chemotherapy by a factor
1.5–2.5.
•At best a doubling of tumor drug concentration when using
standard chemotherapy or non-temperature sensitive liposomal
chemotherapy.
•A 2 to 26 fold increase of tumor drug concentration and an im-
proved homogeneity drug absorption between tumor periphery and
center, when using temperature sensitive liposomal chemotherapy
[133,155].
As explained for many drugs in vivo TER is reported to be maximal
for temperatures between 40.0 and 42.5 °C and a heat duration of
30–90 min. This TER temperature range overlaps very well with the re-
quired temperature range to enhance perfusion/oxygenation and ex-
travasation for many tumors. The only restriction is to avoid long
duration heating at 43 °C to prevent the occurrence of vascular stasis.
For a few drugs a threshold temperature of 42.5 °C is mentioned for
thermal enhancement. Doxorubicin is one the drugs for which this
42.5 °C threshold applies, however, doxorubicin is also the drug mostly
studied using a thermo-sensitive liposome as a smart drug carrier. Here,
the great potential of TSL-encapsulated drugs to enhance tumor drug
concentration outbalances the benefit of TER and priority should be
given to maximally benefit of improved perfusion and extravasation.
When considering the potential contributions via TER versus that of
increased drug concentration using TSL chemotherapy, current biologi-
cal knowledge indicates that the optimal thermal dose should be
40–42 °C for a duration of 30–60min to achievemaximal treatment out-
come. This thermal dose guarantees an effective TER formost drugs and
also the highest enhancement of drug concentration via TSL drug deliv-
ery. Timing of the drug and hyperthermia application should be simul-
taneous for free drugs and while TSL drug application should start
20–30 min after start of the hyperthermia treatment to achieve maxi-
mum drug delivery. Expressed as CEM43 values the proposed thermal
dose translates in a CEM43 of 1 to 15 min.
6. Conclusion
Clinical experience shows that the therapeutic application of hyper-
thermia in large tumors is characterized by a heterogeneous tempera-
ture distribution over the target volume. In general patients toleratedn, Amoderate thermal dose is sufficient for effective free and TSL based
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peratures are associated with discomfort and pain complaints. Further-
more, temperatures around 43 °C have been associated with an
increased probability of acute toxicity and in experimental studies
with vascular collapse. Most importantly, the results reported in ran-
domized studies confirm that this realistic thermal dose target results
in a significant and relevant improved treatment outcome for the com-
bined treatment arm. Therefore, in current clinical practice consensus
exists that the objective of clinical hyperthermia is to aim for target tem-
peratures of 40–42 °C. Extensive research is ongoing to optimize the
thermal dose distribution for the individual patient using new advanced
hyperthermia technology supported by hyperthermia treatment
planning.
When combining chemotherapy and hyperthermia the potential
benefits of each of the biological mechanisms and the optimal temper-
ature at which these mechanisms are triggered and its duration have
to be taken into account to define the best strategy for
thermochemotherapy. Hence, considering the potential benefits of
thermal enhancement versus enhanced drug concentration when
adding hyperthermia to chemotherapy either applied as free drug or
using a thermal sensitive liposomal carrier the optimal thermal dose
for thermochemotherapy should be 40–42 °C for 30–60 min or a
CEM43 of 1–15 min with the chemotherapy simultaneous or 30 min
after starting hyperthermia.
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